The Promise of Peptide Therapeutics
PTG-100 PTG-200 PTG-300
March 22, 2021Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency More

Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies.

Clinical-stage new peptide entities addressing unmet medical needs

Learn More

Executive team with broad industry experience and success in drug development

Learn More

Collaborations with pharma giants and grassroots advocates

Learn More